CellaVision AB (STO:CEVI) CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has received its first orders for the recently launched product, CellaVision® Body Fluid Application from Canada. The customers are all large hospital laboratories in the provinces of Ontario, British Columbia and Nova Scotia.
"It is strategically important for us to be entrusted to deliver a new product this soon after its introduction to the market," says Yvonne Mårtensson, CEO of CellaVision. "This is an example of a newly developed application which can be offered to potential and existing customers. In the long run it will give us recurring revenues."
The official approval for marketing and selling CellaVision Body Fluid Application was authorized by Canada Health in August 2008.
CellaVision has installed CellaVision® DM96 instruments mainly in Europe and North America, and now has an accessible market for the body fluid application. The performance of Body Fluids is a difficult procedure in the clinical laboratory, and as such the efficiency and quality benefits that CellaVision's technology delivers, makes this an attractive offering for them.
Fore more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 708-33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Jupiter, Fl, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.
CellaVision AB
http://www.cellavision.se
ISIN: SE0000683484
Stock Identifier: SSE.CEVI
"It is strategically important for us to be entrusted to deliver a new product this soon after its introduction to the market," says Yvonne Mårtensson, CEO of CellaVision. "This is an example of a newly developed application which can be offered to potential and existing customers. In the long run it will give us recurring revenues."
The official approval for marketing and selling CellaVision Body Fluid Application was authorized by Canada Health in August 2008.
CellaVision has installed CellaVision® DM96 instruments mainly in Europe and North America, and now has an accessible market for the body fluid application. The performance of Body Fluids is a difficult procedure in the clinical laboratory, and as such the efficiency and quality benefits that CellaVision's technology delivers, makes this an attractive offering for them.
Fore more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 708-33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Jupiter, Fl, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.
CellaVision AB
http://www.cellavision.se
ISIN: SE0000683484
Stock Identifier: SSE.CEVI
| Tweet |
 |
Related Companies |
>>> CellaVision AB |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 30 Days: 20) (Since Published: 2230) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
